Frespaciguat + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Jan 18, 2019 → Dec 11, 2020
NCT ID
NCT03744637About Frespaciguat + Placebo
Frespaciguat + Placebo is a phase 1 stage product being developed by Merck for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT03744637. Target conditions include Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05612035 | Phase 2 | Active |
| NCT04425733 | Phase 1 | Withdrawn |
| NCT04370873 | Phase 1 | Completed |
| NCT03744637 | Phase 1 | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension